Drug Profile
Helicobacter pylori DNA vaccine - Valentis
Latest Information Update: 03 Apr 2002
Price :
$50
*
At a glance
- Originator Valentis
- Developer Baylor College of Medicine; M. D. Anderson Cancer Center; Valentis
- Class Bacterial vaccines; DNA vaccines; Gene therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Helicobacter infections
Most Recent Events
- 03 Apr 2002 Discontinued - Preclinical for Helicobacter infections in USA (unspecified route)
- 22 Jun 1999 The GeneMedicine/Megabios merged company is now called Valentis
- 29 Mar 1999 GeneMedicine has merged with Megabios